Table 1.

Baseline patient demographics and disease characteristics

	Durvalumab + EP (n = 18)	EP (n = 16)	All patients (n = 34)
Median age (range), years	67.5 (40–82)	69.5 (46–82)	69 (40–82)
Age group, n (%)
< 65	5 (28)	5 (31)	10 (29)
≥ 65	13 (72)	11 (69)	24 (71)
Sex, n (%)
Men	14 (78)	14 (88)	28 (82)
Women	4 (22)	2 (13)	6 (18)
Median body weight (range), kg	58.0 (50.0–93.0)	60.0 (41.0–91.0)	58.5 (41.0–93.0)
Disease stage, n (%)
IIIB	3 (17)	1 (6)	4 (12)
IV	15 (83)	15 (94)	30 (88)
WHO performance status, n (%)
0	7 (39)	4 (25)	11 (32)
1	11 (61)	12 (75)	23 (68)
Smoking history, n (%)
Never smoker	0	0	0
Former smoker	17 (94)	14 (88)	31 (91)
Current smoker	1 (6)	2 (13)	3 (9)
Brain or CNS metastases, n (%)	1 (6)	3 (19)	4 (12)
Liver metastases, n (%)	10 (56)	7 (44)	17 (50)

CNS central nervous system, EP platinum-etoposide, WHO World Health Organization